These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 28377078)

  • 41. Robustness of nanofiltration for increasing the viral safety margin of biological products.
    Caballero S; Diez JM; Belda FJ; Otegui M; Herring S; Roth NJ; Lee D; Gajardo R; Jorquera JI
    Biologicals; 2014 Mar; 42(2):79-85. PubMed ID: 24485384
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lung polymers in Z alpha1-antitrypsin deficiency-related emphysema.
    Elliott PR; Bilton D; Lomas DA
    Am J Respir Cell Mol Biol; 1998 May; 18(5):670-4. PubMed ID: 9569237
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ensuring the biologic safety of plasma-derived therapeutic proteins: detection, inactivation, and removal of pathogens.
    Cai K; Gierman TM; Hotta J; Stenland CJ; Lee DC; Pifat DY; Petteway SR
    BioDrugs; 2005; 19(2):79-96. PubMed ID: 15807628
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pasteurized, monoclonal antibody factor VIII concentrate: establishing a new standard for purity and viral safety of plasma-derived concentrates.
    Goldsmith JC
    Blood Coagul Fibrinolysis; 2000 Mar; 11(2):203-15. PubMed ID: 10759015
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pain and cyanosis associated with alpha 1-proteinase inhibitor.
    Clark JA; Gross TP
    Am J Med; 1992 Jun; 92(6):621-6. PubMed ID: 1534964
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Virus inactivation and protein recovery in a novel ultraviolet-C reactor.
    Wang J; Mauser A; Chao SF; Remington K; Treckmann R; Kaiser K; Pifat D; Hotta J
    Vox Sang; 2004 May; 86(4):230-8. PubMed ID: 15144527
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product.
    Terpstra FG; Parkkinen J; Tölö H; Koenderman AH; Ter Hart HG; von Bonsdorff L; Törmä E; van Engelenburg FA
    Vox Sang; 2006 Jan; 90(1):21-32. PubMed ID: 16359352
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development of an intravenous immunoglobulin with improved safety and functional activity.
    Roberts PL; Dolan T; Paddick M; Stagg S; More JE
    Biologicals; 2015 Mar; 43(2):123-9. PubMed ID: 25498751
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Purification of alpha 1 proteinase inhibitor from human plasma fraction IV-1 by ion exchange chromatography.
    Chen SX; Hammond DJ; Lang JM; Lebing WR
    Vox Sang; 1998; 74(4):232-41. PubMed ID: 9691404
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Diagnosis of alpha-1 antitrypsin deficiency: modalities, indications and diagnosis strategy.
    Balduyck M; Odou MF; Zerimech F; Porchet N; Lafitte JJ; Maitre B
    Rev Mal Respir; 2014 Oct; 31(8):729-45. PubMed ID: 25391508
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Functional and antigenic concentrations of alpha-1-proteinase inhibitor after administration for the prevention of chronic lung disease of prematurity.
    Stiskal JA; Ito S; Cox DW; Shennan AT; O'Brien KK; Kelly EN; Longley TB; Rabinovitch M; Dunn MS
    Biol Neonate; 1999 Sep; 76(3):134-43. PubMed ID: 10460951
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Virus reduction in an intravenous immunoglobulin by solvent/detergent treatment, ion-exchange chromatography and terminal low pH incubation.
    Roberts PL; Dunkerley C; Walker C
    Biologicals; 2012 Sep; 40(5):345-52. PubMed ID: 22658506
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Purification and analysis of human alpha1-antitrypsin concentrate by a new immunoaffinity chromatography.
    Zhang X; Hou Y; Ding X; Ye S; Cao H; Wang Z; Du X; Xie YW; Li C
    Prep Biochem Biotechnol; 2014 Oct; 44(7):725-37. PubMed ID: 24279822
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comment: comparisons of Aralast and Prolastin, alpha1-protease inhibitors for treatment of alpha1-antitrypsin deficiency.
    Petteway SR
    Ann Pharmacother; 2006 Feb; 40(2):353-4; author reply 354. PubMed ID: 16449545
    [No Abstract]   [Full Text] [Related]  

  • 55. Alpha 1-antitrypsin deficiency and the impact of nursing interventions and treatment with intravenous therapy. An overview.
    Scharnweber K
    J Intraven Nurs; 1999; 22(5):258-64. PubMed ID: 10776189
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prevention of polymerization of M and Z alpha1-Antitrypsin (alpha1-AT) with trimethylamine N-oxide. Implications for the treatment of alpha1-at deficiency.
    Devlin GL; Parfrey H; Tew DJ; Lomas DA; Bottomley SP
    Am J Respir Cell Mol Biol; 2001 Jun; 24(6):727-32. PubMed ID: 11415938
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.
    Kim IS; Choi YW; Kang Y; Sung HM; Shin JS
    J Microbiol Biotechnol; 2008 May; 18(5):997-1003. PubMed ID: 18633304
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hypersensitive mousetraps, alpha1-antitrypsin deficiency and dementia.
    Lomas DA; Lourbakos A; Cumming SA; Belorgey D
    Biochem Soc Trans; 2002 Apr; 30(2):89-92. PubMed ID: 12023831
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Removal of prion infectivity by affinity ligand chromatography during OctaplasLG® manufacturing--results from animal bioassay studies.
    Heger A; Bailey A; Neisser-Svae A; Ertl M; Römisch J; Svae TE
    Vox Sang; 2012 May; 102(4):294-301. PubMed ID: 22070802
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Isolation and characterization of alpha1-proteinase inhibitor from common carp (Cyprinus carpio) seminal plasma.
    Wojtczak M; Całka J; Glogowski J; Ciereszko A
    Comp Biochem Physiol B Biochem Mol Biol; 2007 Nov; 148(3):264-76. PubMed ID: 17681818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.